STOCK TITAN

C4 Therapeutics: RA Capital reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

C4 Therapeutics, Inc. (CCCC) shares were reported as beneficially owned by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and RA Capital managers Peter Kolchinsky and Rajeev Shah. Each reported 13,654,272 shares, or 9.99%, as of September 30, 2026; the cover pages display 9.9%, rounded down due to EDGAR field limits.

The Fund directly holds 8,194,779 common shares. Each of its Class A and Class B warrant classes is exercisable for up to 16,195,000 shares, subject to a blocker that precludes exercise resulting in ownership above 9.99%. The filing also states that current exercises are restricted where they would result in reported beneficial ownership above 13,654,272 shares. The Fund delegated sole voting and dispositive power over its portfolio securities to RA Capital and disclaims beneficial ownership for Section 13(d) purposes.

Reported beneficial ownership 13,654,272 shares Each of the four reporting persons; as of September 30, 2026.
Reported ownership percentage 9.99% Each reporting person; as of September 30, 2026.
Fund direct common shares 8,194,779 shares Common stock held directly by RA Capital Healthcare Fund, L.P.
Warrant capacity per class 16,195,000 shares Each of the Fund's Class A and Class B warrants is exercisable for up to this amount.
Common shares outstanding 123,025,136 shares As of July 31, 2026, as reported in the issuer's Form 10-Q.
Beneficial Ownership Blockers regulatory
"contains a provision (the "Beneficial Ownership Blockers")"
Pre-Funded Warrants technical
"upon the exercise of Pre-Funded Warrants by the Fund"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shared dispositive power regulatory
"Shared Dispositive Power 13,654,272.00"
attribution parties regulatory
"together with its affiliates and other attribution parties"
Section 13(d) regulatory
"for purposes of Section 13(d) of the Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CCCC shares did the reporting persons beneficially own?

Each of the four reporting persons reported 13,654,272 shares, or 9.99%, as of September 30, 2026. The cover pages display 9.9%, rounded down due to EDGAR field limits.

What limits the CCCC warrant exercises?

The Fund's Class A and Class B warrants each contain a blocker that precludes exercise if the Fund, its affiliates and other attribution parties would own more than 9.99% of common stock after exercise. The filing also says current exercises are restricted where they would result in reported beneficial ownership above 13,654,272 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





12529R107

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:11/16/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:11/16/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on October 24, 2025)

Keep reading